Alnylam Pharmaceuticals (United States)

Alnylam Pharmaceuticals (United States)

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2021. Read More.


Open Access Percentage

64%


Total
Publications

513


Total Open
Publications

329


Total
Citations

49K


Open Access
Percentage

64%


Total
Publications

513


Total Open
Publications

329


Total
Citations

49K

Wikipedia

Website

Download

Breakdown

15% 36% 13% 36%

Publisher Open

15%

Both

36%

Other Platform Open

13%

Closed

36%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2003200420052006200720082009201020112012201320142015201620172018201920202021

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

010203040506070Total Publications
2003200420052006200720082009201020112012201320142015201620172018201920202021

Open

Closed

Publisher Open

31%OA Journal

OA Journal 31%

81

Hybrid 31%

81

No Guarantees 38%

98

Other Platform Open

Domain 89%

225

Institution 28%

72

Other Internet 8%

21

Public 8%

20

Preprint 7%

18

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
224
Europe PMC
Domain
193
Massachusetts Institute of Technology - DSpace@MIT
Institution
24
Semantic Scholar
Public
19
Harvard University - Digital Access to Scholarship at Harvard (DASH)
Institution
14
DOI
Other Internet
13
University College London - UCL Discovery
Institution
11
bioRxiv
Preprint
10
medRxiv
Preprint
7
King's College London - Research Portal
Institution
6
1 / 8

Data updated 27 September 2022

Share

Share

Share